Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVNS AVANOS MEDICAL	$10.81 +2.8%	$11.89	$9.30 ▼ $25.36	$501.63M	1.12	520,830 shs	591,653 shs
CATX Perspective Therapeutics	$3.98 +7.0%	$3.71	$1.60 ▼ $16.55	$295.43M	1.17	947,722 shs	748,436 shs
RXST RxSight	$7.35 +10.5%	$10.91	$6.32 ▼ $58.23	$300.76M	1.16	1.03 million shs	1.35 million shs
SIBN SiBone	$15.20 -1.3%	$17.61	$11.70 ▼ $20.05	$655.73M	0.91	433,089 shs	545,410 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVNS AVANOS MEDICAL	-2.36%	-6.73%	-11.92%	-17.48%	-53.28%
CATX Perspective Therapeutics	+1.09%	-4.37%	-6.53%	+45.88%	-69.05%
RXST RxSight	-7.51%	-16.04%	-16.88%	-49.62%	-86.89%
SIBN SiBone	-1.79%	-13.97%	-10.47%	-17.16%	+10.16%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVNS AVANOS MEDICAL	1.6124 of 5 stars	0.0	3.0	0.0	0.9	1.7	2.5
CATX Perspective Therapeutics	2.7161 of 5 stars	4.6	1.0	0.0	3.2	0.8	0.0
RXST RxSight	3.1439 of 5 stars	4.0	4.0	0.0	1.6	1.7	0.6
SIBN SiBone	4.0874 of 5 stars	3.5	3.0	3.3	2.0	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVNS AVANOS MEDICAL	0.00	N/A	N/A	N/A
CATX Perspective Therapeutics	3.18	Buy	$12.56	215.47% Upside
RXST RxSight	1.91	Reduce	$10.00	36.05% Upside
SIBN SiBone	3.00	Buy	$23.67	55.70% Upside

Current Analyst Ratings Breakdown

Latest CATX, RXST, AVNS, and SIBN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	SIBN SiBone	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$25.00
8/8/2025	RXST RxSight	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$16.00 ➝ $8.00
8/8/2025	RXST RxSight	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$9.00 ➝ $8.00
8/8/2025	RXST RxSight	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $11.00
8/5/2025	SIBN SiBone	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$25.00
7/15/2025	RXST RxSight	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$20.00 ➝ $9.00
7/12/2025	CATX Perspective Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/10/2025	RXST RxSight	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$24.00 ➝ $9.00
7/9/2025	RXST RxSight	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underperform ➝ Underperform	$18.00 ➝ $9.00
7/9/2025	RXST RxSight	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$18.00 ➝ $10.00
7/9/2025	RXST RxSight	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$17.00 ➝ $9.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVNS AVANOS MEDICAL	$687.80M	0.73	$11.88 per share	0.91	$18.03 per share	0.60
CATX Perspective Therapeutics	N/A	N/A	N/A	N/A	$2.67 per share	N/A
RXST RxSight	$139.93M	2.15	N/A	N/A	$6.98 per share	1.05
SIBN SiBone	$167.18M	3.92	N/A	N/A	$3.98 per share	3.82

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVNS AVANOS MEDICAL	-$392.10M	-$10.07	N/A	6.25	N/A	-66.89%	6.16%	4.57%	10/29/2025 (Estimated)
CATX Perspective Therapeutics	-$46.51M	N/A	0.00	N/A	N/A	-4,096.66%	-27.40%	-23.16%	8/13/2025 (Estimated)
RXST RxSight	-$27.45M	-$0.80	N/A	N/A	N/A	-21.93%	-11.55%	-10.27%	N/A
SIBN SiBone	-$30.91M	-$0.56	N/A	N/A	N/A	-12.83%	-14.20%	-10.38%	N/A

Latest CATX, RXST, AVNS, and SIBN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	N/A	CATX Perspective Therapeutics	-$0.30	N/A	N/A	N/A	$0.17 million	N/A
8/7/2025	Guidance Update	RXST RxSight	-$0.04	-$0.08	-$0.04	-$0.29	$39.78 million	$33.64 million
8/5/2025	Q2 2025	AVNS AVANOS MEDICAL	$0.18	$0.17	-$0.01	-$1.66	$165.50 million	$175.00 million
8/4/2025	Q2 2025	SIBN SiBone	-$0.19	-$0.14	+$0.05	-$0.14	$48.12 million	$48.63 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVNS AVANOS MEDICAL	N/A	N/A	N/A	N/A	N/A
CATX Perspective Therapeutics	N/A	N/A	N/A	N/A	N/A
RXST RxSight	N/A	N/A	N/A	N/A	N/A
SIBN SiBone	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVNS AVANOS MEDICAL	0.12	2.64	1.58
CATX Perspective Therapeutics	N/A	9.60	9.60
RXST RxSight	N/A	12.68	11.65
SIBN SiBone	0.21	8.38	7.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVNS AVANOS MEDICAL	95.17%
CATX Perspective Therapeutics	54.66%
RXST RxSight	78.78%
SIBN SiBone	98.11%

Insider Ownership

Company	Insider Ownership
AVNS AVANOS MEDICAL	2.64%
CATX Perspective Therapeutics	3.72%
RXST RxSight	9.57%
SIBN SiBone	3.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVNS AVANOS MEDICAL	2,227	46.40 million	45.18 million	Optionable
CATX Perspective Therapeutics	70	74.23 million	65.21 million	Optionable
RXST RxSight	220	40.92 million	37.00 million	Optionable
SIBN SiBone	350	43.14 million	41.46 million	Optionable

CATX, RXST, AVNS, and SIBN Headlines

Recent News About These Companies

Insider Selling: SiBone (NASDAQ:SIBN) Director Sells 12,132 Shares of Stock

August 12 at 4:53 AM | insidertrades.com

SiBone (NASDAQ:SIBN) Stock Rating Lowered by Wall Street Zen

August 10 at 3:32 AM | marketbeat.com

FY2025 EPS Estimates for SiBone Boosted by Cantor Fitzgerald

August 9 at 9:28 AM | marketbeat.com

FY2025 EPS Estimates for SiBone Raised by Cantor Fitzgerald

August 9 at 3:19 AM | americanbankingnews.com

SiBone (NASDAQ:SIBN) Shares Down 13.1% - Here's What Happened

August 6, 2025 | marketbeat.com

SiBone (NASDAQ:SIBN) Earns "Overweight" Rating from Cantor Fitzgerald

August 6, 2025 | marketbeat.com

SiBone (NASDAQ:SIBN) Issues Quarterly Earnings Results

August 5, 2025 | marketbeat.com

SI-Bone Reports Strong Q2 2025 Financial Results

August 5, 2025 | msn.com

SI-BONE, Inc. (SIBN) Q2 2025 Earnings Call Transcript

August 5, 2025 | seekingalpha.com

SI-BONE, Inc. 2025 Q2 - Results - Earnings Call Presentation

August 4, 2025 | seekingalpha.com

Si-Bone (SIBN) Reports Q2 Loss, Beats Revenue Estimates

August 4, 2025 | zacks.com

SI-BONE, Inc. Reports Financial Results for the Second Quarter 2025 and Raises 2025 Guidance

August 4, 2025 | globenewswire.com

Universal Beteiligungs und Servicegesellschaft mbH Acquires New Holdings in SiBone (NASDAQ:SIBN)

August 3, 2025 | marketbeat.com

SiBone (SIBN) Projected to Post Earnings on Monday

August 3, 2025 | americanbankingnews.com

SI-BONE To Present at Canaccord Genuity 45th Annual Growth Conference on August 12, 2025

July 29, 2025 | globenewswire.com

SiBone (SIBN) Projected to Post Quarterly Earnings on Monday

July 28, 2025 | marketbeat.com

Victory Capital Management Inc. Raises Stock Holdings in SiBone (NASDAQ:SIBN)

July 25, 2025 | marketbeat.com

Legato Capital Management LLC Acquires 36,649 Shares of SiBone (NASDAQ:SIBN)

July 24, 2025 | marketbeat.com

SI-BONE To Report Second Quarter 2025 Financial Results on August 4, 2025

July 14, 2025 | globenewswire.com

Insider Selling: SiBone (NASDAQ:SIBN) CEO Sells 757 Shares of Stock

July 8, 2025 | insidertrades.com

All You Need to Know About Si-Bone (SIBN) Rating Upgrade to Buy

July 7, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CATX, RXST, AVNS, and SIBN Company Descriptions

AVANOS MEDICAL NYSE:AVNS

$10.81 +0.29 (+2.77%)

Closing price 03:59 PM Eastern

Extended Trading

$10.80 -0.02 (-0.15%)

As of 04:30 PM Eastern

Avanos Medical, Inc., a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides a portfolio of non-opioid pain solutions, including surgical pain and recovery products, such as ON-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy; OrthogenRx's knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.

Perspective Therapeutics NYSE:CATX

$3.98 +0.26 (+6.99%)

Closing price 04:00 PM Eastern

Extended Trading

$3.95 -0.03 (-0.75%)

As of 05:28 PM Eastern

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

RxSight NASDAQ:RXST

$7.35 +0.70 (+10.53%)

Closing price 04:00 PM Eastern

Extended Trading

$7.25 -0.10 (-1.37%)

As of 05:27 PM Eastern

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

SiBone NASDAQ:SIBN

$15.20 -0.20 (-1.30%)

Closing price 04:00 PM Eastern

Extended Trading

$15.22 +0.03 (+0.16%)

As of 04:10 PM Eastern

SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time